213 related articles for article (PubMed ID: 31015448)
1. A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors.
Jumani RS; Hasan MM; Stebbins EE; Donnelly L; Miller P; Klopfer C; Bessoff K; Teixeira JE; Love MS; McNamara CW; Huston CD
Nat Commun; 2019 Apr; 10(1):1862. PubMed ID: 31015448
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic screening techniques for
Love MS; McNamara CW
Expert Opin Drug Discov; 2021 Jan; 16(1):59-74. PubMed ID: 32892652
[No Abstract] [Full Text] [Related]
3. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
Love MS; Beasley FC; Jumani RS; Wright TM; Chatterjee AK; Huston CD; Schultz PG; McNamara CW
PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005373. PubMed ID: 28158186
[TBL] [Abstract][Full Text] [Related]
4. Cryptosporidiosis Drug Discovery: Opportunities and Challenges.
Manjunatha UH; Chao AT; Leong FJ; Diagana TT
ACS Infect Dis; 2016 Aug; 2(8):530-7. PubMed ID: 27626293
[TBL] [Abstract][Full Text] [Related]
5. Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis.
Lunde CS; Stebbins EE; Jumani RS; Hasan MM; Miller P; Barlow J; Freund YR; Berry P; Stefanakis R; Gut J; Rosenthal PJ; Love MS; McNamara CW; Easom E; Plattner JJ; Jacobs RT; Huston CD
Nat Commun; 2019 Jun; 10(1):2816. PubMed ID: 31249291
[TBL] [Abstract][Full Text] [Related]
6. A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box.
Jumani RS; Bessoff K; Love MS; Miller P; Stebbins EE; Teixeira JE; Campbell MA; Meyers MJ; Zambriski JA; Nunez V; Woods AK; McNamara CW; Huston CD
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339392
[TBL] [Abstract][Full Text] [Related]
7. A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis.
Manjunatha UH; Vinayak S; Zambriski JA; Chao AT; Sy T; Noble CG; Bonamy GMC; Kondreddi RR; Zou B; Gedeck P; Brooks CF; Herbert GT; Sateriale A; Tandel J; Noh S; Lakshminarayana SB; Lim SH; Goodman LB; Bodenreider C; Feng G; Zhang L; Blasco F; Wagner J; Leong FJ; Striepen B; Diagana TT
Nature; 2017 Jun; 546(7658):376-380. PubMed ID: 28562588
[TBL] [Abstract][Full Text] [Related]
8. Novel treatment strategies and drugs in development for cryptosporidiosis.
Chavez MA; White AC
Expert Rev Anti Infect Ther; 2018 Aug; 16(8):655-661. PubMed ID: 30003818
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in genetic manipulation of Cryptosporidium.
Vinayak S
Curr Opin Microbiol; 2020 Dec; 58():146-152. PubMed ID: 33161368
[TBL] [Abstract][Full Text] [Related]
10. Cryptic parasite revealed improved prospects for treatment and control of human cryptosporidiosis through advanced technologies.
Jex AR; Smith HV; Nolan MJ; Campbell BE; Young ND; Cantacessi C; Gasser RB
Adv Parasitol; 2011; 77():141-73. PubMed ID: 22137584
[TBL] [Abstract][Full Text] [Related]
11. Treatment of cryptosporidiosis: nitazoxanide yes, but we can do better.
Caravedo MA; White AC
Expert Rev Anti Infect Ther; 2023 Feb; 21(2):167-173. PubMed ID: 36533398
[TBL] [Abstract][Full Text] [Related]
12. Use-case scenarios for an anti-Cryptosporidium therapeutic.
Ashigbie PG; Shepherd S; Steiner KL; Amadi B; Aziz N; Manjunatha UH; Spector JM; Diagana TT; Kelly P
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009057. PubMed ID: 33705395
[TBL] [Abstract][Full Text] [Related]
13. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis.
Janes J; Young ME; Chen E; Rogers NH; Burgstaller-Muehlbacher S; Hughes LD; Love MS; Hull MV; Kuhen KL; Woods AK; Joseph SB; Petrassi HM; McNamara CW; Tremblay MS; Su AI; Schultz PG; Chatterjee AK
Proc Natl Acad Sci U S A; 2018 Oct; 115(42):10750-10755. PubMed ID: 30282735
[TBL] [Abstract][Full Text] [Related]
14. Drug treatment and novel drug target against Cryptosporidium.
Gargala G
Parasite; 2008 Sep; 15(3):275-81. PubMed ID: 18814694
[TBL] [Abstract][Full Text] [Related]
15. Opportunities and Challenges in Developing a
Jumani RS; Blais J; Tillmann HC; Segal F; Wetty D; Ostermeier C; Nuber N; Lakshman J; Aziz N; Chandra R; Chen WH; Chappell CL; Diagana TT; Manjunatha UH
ACS Infect Dis; 2021 May; 7(5):959-968. PubMed ID: 33822577
[TBL] [Abstract][Full Text] [Related]
16. Metal-captured inhibition of pre-mRNA processing activity by CPSF3 controls
Swale C; Bougdour A; Gnahoui-David A; Tottey J; Georgeault S; Laurent F; Palencia A; Hakimi MA
Sci Transl Med; 2019 Nov; 11(517):. PubMed ID: 31694928
[No Abstract] [Full Text] [Related]
17. New Tools for Cryptosporidium Lead to New Hope for Cryptosporidiosis.
Ward HD
Trends Parasitol; 2017 Sep; 33(9):662-664. PubMed ID: 28750950
[TBL] [Abstract][Full Text] [Related]
18. Management of a Cryptosporidium hominis outbreak in a day-care center.
Vandenberg O; Robberecht F; Dauby N; Moens C; Talabani H; Dupont E; Menotti J; van Gool T; Levy J
Pediatr Infect Dis J; 2012 Jan; 31(1):10-5. PubMed ID: 22094626
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial.
Nachipo P; Hermann D; Quinnan G; Gordon MA; Van Voorhis WC; Iroh Tam PY
Trials; 2018 Aug; 19(1):456. PubMed ID: 30139372
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium hominis.
Lee S; Ginese M; Beamer G; Danz HR; Girouard DJ; Chapman-Bonofiglio SP; Lee M; Hulverson MA; Choi R; Whitman GR; Ojo KK; Arnold SLM; Van Voorhis WC; Tzipori S
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
